Pfizer Inc.’s next-generation oral JAK1 inhibitor, abrocitinib, is likely to be a strong competitor to Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for treating atopic dermatitis, judging by top-line results from a third Phase III study which showed a higher dose of abrocitinb was significantly superior to the interleukin-4/IL-13 inhibitor, dupilumab, in reducing itch after the first two weeks of therapy.
Having a quicker effect on symptoms could be an important differentiator for abrocitinib in its likely marketing battle with the entrenched dupilimab, which has established a leading position in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?